Monthly Journal article review: Vimmi Kang PGY 2

Slides:



Advertisements
Similar presentations
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Advertisements

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
A Randomized Trial of Protocol-Based Care for Early Septic Shock Andrea Caballero, MD January 15, 2015 LSU Journal Club The ProCESS Investigators. N Engl.
Pablo M. Bedano M.D. Community Regional Cancer Care.
Epoetin Alfa & Increased Mortality Maria Shin, Pharm.D. Pharmacy Resident (PGY-1) Kingsbrook Jewish Medical Center Clinical Instructor of Pharmacy Practice.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
THE TRISS TRIAL Holst, L et al. Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock. New England Journal of Medicine October 9, 2014.
Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-
Is that Hemoglobin High Enough? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Risks and Indications for RBCs Transfusions David Stroncek, MD Chief, Laboratory Services Section Department of Transfusion Medicine, Clinical Center,
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.
Sarah Struthers, MD March 19, 2015
Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院 劉慧萍藥師.
Iatrogenic Anemia in the ICU Anh Nguyen, MD, MPH, PGY2.
Red Cell Transfusion in Critical Care Patients Alan Tinmouth, MD MSc University of Ottawa Centre for Transfusion Research, Ottawa Health Research Institute.
Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.
Reduction of RBC transfusions based on standardized hemoglobin evaluation for adult non-ICU patients Kathryn Curcione RN, BSN, ONC, NE-BC, Molly Rankin,
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Monthly Journal article review: Vimmi Kang PGY 2
Impact of a PRUDENT © Red Blood Cell Transfusion Strategy in Pediatric HSCT and Oncology Patients Results from the CHB Experience © 2009 All rights.
4S: Scandinavian Simvastatin Survival Study
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
A pilot randomized controlled trial Registry #: NCT
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Angela Aziz Donnelly April 5, 2016
Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema Alasdair Gray, M.D., Steve Goodacre, Ph.D., David E. Newby, M.D., Moyra Masson, M.Sc., Fiona.
Geriatrics Journal Club Yee Chuan Ang, MD Geriatric Medicine Fellow PGY-4 Boston University School of Medicine.
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven.
Jason P. Lott, Theodore J. Iwashyna, Jason D. Christie, David A. Asch, Andrew A. Kramer, and Jeremy M. Kahn Am J Respir Crit Care Med Vol 179. pp 676–683,
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
Jakutis G.1, Polevoda V.1, Serpytis R.2, Serpytis P.2,3
Updates From NOTION: The First All-Comer TAVR Trial
Surgical ICU, Heart Institute University of São Paulo
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
The ADEMEX Trial Adequacy of PD in Mexico Reference
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
HOPE: Heart Outcomes Prevention Evaluation study
AUDIT OF RED BLOOD CELL TRANSFUSION PRACTICE IN THE ITU SETTING
The IDEAL Study Reference
Consultant CPD, November 23rd 2016
Don’t Nudge Me: The Limits of Behavioral Economics in Medicine
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Valsartan in Acute Myocardial Infarction Trial Investigators
Critical Reading of Clinical Study Results
Blood Transfusion Evidence-Based Blood Therapeutics “7 is the NEW 10”
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Systolic Blood Pressure Intervention Trial (SPRINT)
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
European Heart Association Journal 2007 April
Dr. PJ Devereaux on behalf of POISE Investigators
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
PPI prophylaxis for GI bleeding in ICU
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Atlantic Cardiovascular Patient Outcomes Research Team
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
Presentation transcript:

Monthly Journal article review: Vimmi Kang PGY 2 The New England Journal of Medicine: A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care Monthly Journal article review: Vimmi Kang PGY 2

Importance Transfusions are a necessary part of managing critical patients. Different views of when to transfuse in regards to risks versus benefits Microcirculatory and immunosuppressive complications of red cell transfusions Concern about supply and safety of blood Two recent studies suggested that anemia increases risk of death in patients with cardiac disease and in critical ill patients Prompted the routine use of transfusion in hgb>10g/dL Optimal transfusion practice for various types of critically ill patients with anemia has not been established

Background To determine whether a restrictive strategy of red cell transfusion and a liberal strategy produced equivalent results in critically ill patients. Rates of death from all causes at 30 days and the severity of organ dysfunction was compared between the two groups.

Enrolled patients in Canada between November 1994 and November 1997 Study was published in 1999 Enrolled patients in Canada between November 1994 and November 1997 Exclusion criteria Age less than 16yrs Inability to receive blood products Active blood loss at the time of enrollment Requirement of >3prbc OR Decrease in hgb by 3 in the preceding 12 hours Chronic anemia (hgb <9) At least one occasion more than 1 month prior to hospital admission Pregnancy Brain death or imminent death (within 24hrs) Question on the part of attending physicians whether to withhold or withdraw ongoing treatment Admission after a routine cardiac procedure

Method Enrolled 838 critically ill patients with euvolemia after initial treatment, with hemoglobin conc of less than 9 g/dL within 72 hours of admission to the ICU 418 of those were randomly assigned to the restrictive group 420 patients to the liberal group

Restrictive Strategy of transfusion RBC were transfused if hemoglobin concentration dropped <7.0g/dL Hemoglobin concentration was maintained at 7 to 9 g/dL

Liberal Strategy of red cell transfusion Transfusion was given if hemoglobin concentrations fell below 10g/dL Hemoglobin concentrations were maintained at 10 to 12 g/dL

Base Line Characteristics of the Study Patients

Hgb was measured after each unit of transfusion APACHE II Assessed on the day of admission to the ICU Scores range from 0 to 71 MODS Scores range from 0 to 24

Outcome measures Primary outcome Secondary outcome Death from all causes in 30 days Secondary outcome 60 day rates of death Mortality rates during ICU stay Mortality rated during hospitialization Measures of organ failure and dysfunction

Outcomes

Results 30 day mortality between the two groups were similar 18.7% vs 23.3% Exceptions Rates were significantly lower in the restrictive group among patients who had a score <20 in Acute Physiology and Chronic Health Evaluation II 8.7% vs 16.1% Among patient less than 55yrs of age 5.7% vs 13% But not among patients with significant cardiac disease 20.5% vs 22.9% Mortality rate during hospitalization was significantly lower in the restrictive strategy group 22.2% vs 28.1%

Cardiac events, primarily pulmonary edema and Myocardial infarction were more frequent in the liberal-strategy group than in the restrictive strategy group during ICU stay

Conclusions Restrictive strategy of red cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients with the possible exception of patients with acute myocardial infarction and unstable angina

critique Hypothesis: oxygen delivery should be increased or maintained at high levels to minimize the effects of tissue hypoxis caused by disease processes that interfere with oxygen delivery or the body ability to extract oxygen Many randomized, controlled clinical trials addressed this hypothesis Trials did not make inferences on the optimal strategy for red cell transfusion

Results from previous studies were not correlated with this study “Increasing severity of anemia was associated with a disproportionate increase in mortality rates among patients with ischemic heart disease” However with this study, it did not show increase in mortality or adverse outcomes in patients with cardiac disease under the restrictive transfusion group when compared to the liberal group Greater proportion of patients that ‘refused’ to be included this study were of the cardiac disease category Attending physicians Can affect generalization of the results, especially myocardial infarction and angina Not enough data to make any generalization

Did not adhere to the liberal vs restrictive strategy once patient was transferred out of ICU What affect does that have on the secondary outcomes